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Background: Acinetobacter baumannii is well-recognized as an important nosocomial pathogen, however, due to
their intrinsic resistance to several antibiotics, treatment options are limited. Synergistic effects between antibiotics
and medicinal plants, particularly their active components, have intensively been studied as alternative approaches.
Methods: Fifty-one ethanol extracts obtained from 44 different selected medicinal plant species were tested for
resistance modifying agents (RMAs) of novobiocin against A. baumannii using growth inhibition assay.
Results: At 250 μg/ml, Holarrhena antidysenterica, Punica granatum, Quisqualis indica, Terminalia bellirica, Terminalia
chebula, and Terminalia sp. that possessed low intrinsic antibacterial activity significantly enhanced the activity of
novobiocin at 1 μg/ml (1/8xminimum inhibitory concentration) against this pathogen. Holarrhena antidysenterica at
7.8 μg/ml demonstrated remarkable resistant modifying ability against A. baumannii in combination with
novobiocin. The phytochemical study revealed that constituents of this medicinal plant contain alkaloids,
condensed tannins, and triterpenoids.
Conclusion: The use of Holarrhena antidysenterica in combination with novobiocin provides an effective alternative
treatment for multidrug resistant A. baumannii infections.Background
An underestimated nosocomial pathogen, Acinetobacter
baumannii, is now widely acknowledged as a common bac-
terium in hospital irrigation and intravenous solutions. It
possesses inherent multidrug-resistance (MDR) and the
ability to rapidly colonize and infect patients. Moreover, the
emergence of acquired MDR by A. baumannii to conven-
tional antibiotics presents a serious therapeutic problem in
the treatment of the infections [1,2]. Several investigations
suggested that synergy effects of plant secondary metabo-
lites and conventional antibiotics could be an alternative
way to increase the bacterial susceptibility [3-6].
Plants, particularly ethnomedicinal plants are important
sources of natural products. They are rich in a wide variety
of secondary metabolites such as tannins, terpenoids, alka-
loids, and flavonoids and have been well-established to
possess antimicrobial properties [7]. Many plants have* Correspondence: supayang.v@psu.ac.th
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distribution, and reproduction in any mediumbeen evaluated not only for their inherent antimicrobial
activity, but also for their action as a resistant modifying
agent (RMA) [4].
Novobiocin, a Gyr B inhibitor, is an effective aminocou-
marin drug for the treatment of Gram-positive bacterial
infections. However, its low level of activity against Gram-
negative pathogens causes a major limitation [8]. Although,
several investigations observed synergy and mechanisms of
action between natural products and synthetic drugs in
effectively combating Gram positive bacterial infections [5],
there are a few RMA effective for use with A. baumannii
[9,10]. Therefore, the aim of this study was to further
explore the resistant modifying activity of a wide range of
medicinal plants according to their ethnobotanical basis in
combination with novobiocin against A. baumannii.Methods
Bacterial strain and culture condition
Acinetobacter baumannii ATCC 19606 was employed in
this study as a model reference strain. The strain was
susceptible to ciprofloxacin, colistin, imipenem, andCentral Ltd. This is an Open Access article distributed under the terms of the
creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Table 1 Intrinsic antibacterial activity and resistant modifying ability of crude extract (250 μg/ml) in combination with
novobiocin (1/8xMIC) against Acinetobacter baumannii ATCC 19606
Botanical names Family name Part used %Growth inhibitiona ± SDb Interpretationc
PE PE+NOV
1 Aegle marmelos (L.) Corr. Serr. Rutaceae Fruit 22.10 ± 0.68 27.10 ± 1.38 No synergy
2 Ardisia colorata Roxb. Primulaceae Fruit 30.17 ± 2.56 39.00 ± 6.09 Synergy
3 Asclepias curassavica L. Asclepiadaceae Wood 40.81 ± 0.28 43.59 ± 1.78 No synergy
4 Centella asiatica (L.) Urb. Apiaceae Whole 19.09 ± 1.06 23.93 ± 2.87 No synergy
5 Cinnamomum bejolghota
(Buch.-Ham.) Sweet
Lauraceae Wood 58.84 ± 1.37 59.92 ± 1.78 No synergy
Bark 55.62 ± 4.98 62.44 ± 2.91 No Synergy
6 Cinnamomum porrectum
(Roxb.) Kosterm.
Lauraceae Wood 29.72 ± 6.54 26.06 ± 5.21 No synergy
Bark 56.88 ± 2.14 63.31 ± 4.87 No synergy
7 Curcuma longa L. Zingiberaceae Rhizome 86.91 ± 2.64 88.78 ± 2.08 No synergy
8 Curcuma zedoaria
(Christm.) Roscoe
Zingiberaceae Rhizome 77.73 ± 0.48 79.59 ± 2.62 No synergy
9 Derris scandens Benth. Leguminosea Stem 49.01 ± 2.37 47.31 ± 3.84 No synergy
10 Dracaena loureiri Gagnep. Agavaceae Wood 30.08 ± 0.99 29.49 ± 3.19 No synergy
11 Dryopteris syrmatica
(Willd.) Kuntze
Dryopteridaceae Stem 17.59 ± 0.41 26.66 ± 5.32 Synergy
12 Eleutherine americana
(Aubl.) Merr. ex K.
Iridaceae Bulb 17.87 ± 1.89 22.26 ± 3.12 No synergy
13 Euphorbia thymifolia L. Euphorbiaceae Whole plant 53.64 ± 0.90 73.99 ± 0.88 Synergy
14 Garcinia mangostana L. Clusiaceae Pericarp 93.25 ± 3.65 90.48 ± 3.37 No synergy
15 Gymnopetalum cochinchinensis
(Lour.) Kurz
Cucurbitaceae Fruit 26.17 ± 0.59 32.45 ± 4.39 No synergy
16 Holarrhena antidysenterica
(L.) Wall. ex A. DC.
Apocynaceae Bark 65.88 ± 0.11 94.04 ± 0.59* Synergy
17 Impatiens balsamina L. Balsaminaceae Stem 9.77 ± 0.30 12.40 ± 1.56 No synergy
18 Manilkara achras (Mill.) Fosb. Sapotaceae Fruit 56.59 ± 1.02 63.06 ± 2.97 No synergy
19 Millingtonia hortensis L.f. Bignoniaceae Flower 28.97 ± 4.30 54.08 ± 0.83 Synergy
20 Mitragyna speciosa Korth. Rubiaceae Leaf 43.33 ± 2.40 66.15 ± 0.26 Synergy
21 Momordica charantia L. Cucurbitaceae Vine 22.26 ± 0.85 25.79 ± 3.10 No synergy
22 Morinda citrifolia L. Rubiaceae Fruit 16.96 ± 0.63 25.86 ± 1.22 Synergy
23 Murdannia loriformis (Hassk.)
R. Rao & Kammathy
Commilinaceae Whole plant 16.42 ± 1.51 22.04 ± 1.67 No synergy
24 Oroxylum indicum (L.) Vent. Bignoniaceae Leaf 67.18 ± 1.59 71.30 ± 5.28 No synergy
25 Peltophorum pterocarpum
(DC.) Backer ex K. Heyne
Fabaceae Flower 42.80 ± 0.43 47.83 ± 4.49 No synergy
Bark 78.26 ± 0.60 88.75 ± 6.10 Synergy
26 Piper betle L. Piperaceae Leaf 42.72 ± 0.13 39.92 ± 3.43 No synergy
27 Piper nigrum L. Piperaceae Fruit 38.07 ± 1.96 42.24 ± 2.60 No synergy
Seed 29.07 ± 0.75 31.47 ± 3.27 No synergy
28 Piper retrofractum Vahl Piperaceae Fruit 44.02 ± 1.08 49.80 ± 4.19 No synergy
29 Piper sarmentosum Roxb Piperaceae Leaf 20.70 ± 0.88 25.02 ± 0.62 No synergy
30 Pluchea indica (L.) Less. Asteraceae Leaf 26.64 ± 0.97 53.59 ± 3.60* Synergy
31 Psidium guajava L. Myrtaceae Leaf 71.24 ± 2.00 81.19 ± 1.50* Synergy
32 Punica granatum L. Puniceaceae Pericarp 72.58 ± 1.20 99.29 ± 0.63* Synergy
33 Quercus infectoria G.Olivier Fagaceae Gall 89.09 ± 0.15 88.77 ± 1.00 No synergy
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Table 1 Intrinsic antibacterial activity and resistant modifying ability of crude extract (250 μg/ml) in combination with
novobiocin (1/8xMIC) against Acinetobacter baumannii ATCC 19606 (Continued)
34 Quisqualis indica L. Combretaceae Flower 79.22 ± 0.28 94.63 ± 2.62* Synergy
35 Rhizophora mucronata Lam. Rhizophoraceae Fruit 44.64 ± 0.59 53.35 ± 2.56 Synergy
Bark 42.68 ± 8.20 53.03 ± 4.95 Synergy
36 Rhodomyrtus tomentosa
(Aiton) Hassk.
Myrtaceae Stem 77.01 ± 1.28 81.81 ± 4.01 No synergy
37 Sandoricum indicum Cav. Meliaceae Root 65.24 ± 1.32 66.94 ± 2.13 No synergy
38 Tamarindus indica L. Fabaceae Leaf 19.76 ± 1.55 25.03 ± 3.45 No synergy
39 Terminalia bellirica
(Gaertn.) Roxb.
Combretaceae Fruit 74.79 ± 0.53 95.68 ± 1.14* Synergy
40 Terminalia chebula
(Gaertn.) Retz.
Combretaceae Fruit 61.25 ± 0.42 94.33 ± 1.95* Synergy
41 Terminalia sp. Combretaceae Fruit 79.53 ± 0.24 95.92 ± 1.10* Synergy
42 Theobroma cacao L. Sterculiaceae Pericarp 17.35 ± 0.74 22.81 ± 0.68 No synergy
Seed 19.25 ± 1.08 29.61 ± 4.13 Synergy
43 Vitex trifolia L. Verbenaceae Leaf 22.12 ± 0.68 28.65 ± 3.57 No synergy
44 Xylocarpus granatum
J. Koenig.
Meliaceae Pericarp 52.39 ± 3.48 53.27 ± 1.91 No synergy
Seed 44.27 ± 5.13 54.55 ± 3.66 No synergy
Percentage of growth inhibition of novobiocin against A. buamannii ATCC 19606 was 6.67%.
aPercentage of growth inhibition in the present of plant extract (PE) and plant extract in combination with novobiocin (PE+NOV) against A. buamannii ATCC 19606.
bSD Standard Deviation.
cSynergy: (PE +NOV)> (PE) + (NOV); No synergy: (PE +NOV)< (PE) + (NOV) [6].
*P< 0.01: Significantly different from the effect of plant extract.
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mycin, erythromycin, and gentamicin which conducted by
disc diffusion method [11]. Well-isolated colonies of A.
baumannii ATCC 19606 were grown in Mueller Hinton
Broth (MHB) (Difco Laboratories, Detroit, MI) at 37°C for
18–24 h. The culture density was adjusted to McFarland
standards No. 0.5 and resuspended in MHB to obtain a
final concentration of 1 × 106 cfu/ml.
Medicinal plant materials
Tested medicinal plants are shown in Table 1. Fifty-one
ethanol extracts of 44 Thai medicinal plant species were
kindly provided by the Natural Products Research Center,
Prince of Songkla University, Hat Yai, Thailand [12]. Col-
lected plant materials were washed with distilled water and
dried at 60°C overnight. Ground plant material was macer-
ated with 95% ethanol (1:2 w/v) for 7 days. The extract was
filtered and evaporated using rotary evaporator at 45°C until
it became completely dry. A stock solution (200 mg/ml)
was prepared by dissolving 0.2 g of the dried extract in 1 ml
of dimethylsulfoxide (DMSO) (Merck, Germany) and
stored at −20°C.
Determination of minimum inhibitory concentration (MIC)
of novobiocin
The MIC of novobiocin was determined by the broth
microdilution method as described by the Clinical and
Laboratory Standard Institute (CLSI) [13].Intrinsic antibacterial activity and resistant modifying
ability of medicinal plant extracts
Intrinsic antibacterial activities were determined by growth
inhibition assays [9]. The bacterial culture (100 μl) was
inoculated into a 96-well microtiter plate containing 50 μl
of crude extracts (1,000 μg/ml) and 50 μl of MHB and
then incubated at 37°C for 18 h. The intrinsic antibacterial
activity was exhibited as the percentage of growth inhib-
ition and calculated from the following equation:
%Growth inhibition ¼ ODA–ODBð Þ  100½ =ODA
Where ODA is Optical density (OD) 595 nm of bacteria
culture in MHB supplemented with 1%DMSO as positive
control and ODB is OD 595 nm of the bacterial culture in
MHB supplemented with plant extracts.
Resistant modifying ability of the extracts was
observed by adding of 50 μl novobiocin at a concentra-
tion of 1/8xMIC (1 μg/ml) into the tested plate instead
of MHB. This biological activity was exhibited as the
percentage of growth inhibition as well but calculated
from the following equation, where ODC is OD 595 nm
of the bacterial culture in MHB supplemented with the
plant extract in combination with novobiocin:
%Growth inhibition ¼ ODA–ODCð Þ  100½ =ODA
Effective medicinal plants that demonstrated a synergistic
effect with novobiocin and exhibited bacterial growth
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ments. The efficacy of combination therapy of the promis-
ing medicinal plants with novobiocin was additionally
determined by measuring the resistant modifying capabil-
ities of the extracts at varying concentrations ranging from
7.8 to 250 μg/ml.
Phytochemical screening methods
Phytochemical screening tests for alkaloids, condensed
tannins, flavonoids, hydrolysable tannins, steroids, and
triterpenes were qualitatively analyzed by standard
colour tests as previously described [14].Figure 1 Bacterial growth inhibition of Holarrhena antidysenterica (A), P
Terminalia chebula (E), and Terminalia sp. (F) ethanol extracts (○) and th
Acinetobacter baumannii ATCC 19606. Percentage of bacterial growth inhiResults and discussion
Intrinsic resistance of A. baumannii to novobiocin was
observed with MIC value at 8 μg/ml. As shown in
Table 1, 48 out of 51 tested ethanol extracts at concen-
tration of 250 μg/ml had low inherent antibacterial activ-
ity (% of bacterial growth inhibition was less than 80%).
In combination with the antibiotic, the extracts of 18
medicinal plants demonstrated synergistic interaction
against A. baumannii. Interestingly, the bacterial growth
inhibition in the presence of novobiocin in combination
with the extracts of Holarrhena antidysenterica, Punica
granatum, Quisqualis indica, Terminalia bellirica,unica granatum (B), Quisqualis indica (C), Terminalia bellirica (D),
e extracts in combination with 1/8xMIC of novobiocin (●) against
bition of 1/8xMIC of novobiocin on this pathogen was 6.67%.
Table 2 Extraction yields and phytochemical constituents of tested medicinal plant extracts
Botanical names Part used Yield (%; w/w)a Phytochemical constituentsb
1 2 3 4 5 6
1 Aegle marmelos (L.) Corr. Serr. Fruit 5.3 + + + - + -
2 Ardisia colorata Roxb. Fruit 4.4 + + - - + -
3 Asclepias curassavica L. Wood 0.9 + + - - - -
4 Centella asiatica (L.) Urb. Whole 6.0 + - - - + -
5 Cinnamomum bejolghota
(Buch.-Ham.) Sweet
Wood 2.2 + + - - + -
Bark 14.6 + - - + + -
6 Cinnamomum porrectum
(Roxb.) Kosterm.
Wood 11.2 - - - - + -
Bark 7.0 + + - - + -
7 Curcuma longa L. Rhizome 13.9 + + + - + -
8 Curcuma zedoaria
(Christm.) Roscoe
Rhizome 13.9 + + + - - +
9 Derris scandens Benth. Stem 3.2 - + - - + -
10 Dracaena loureiri Gagnep. Wood 16.9 - - - - - +
11 Dryopteris syrmatica
(Willd.) Kuntze
Stem 4.5 + + - - + -
12 Eleutherine americana
(Aubl.) Merr. ex K.
Bulb 4.8 + + - - - -
13 Euphorbia thymifolia L. Whole plant 1.3 - + - - + -
14 Garcinia mangostana L. Pericarp 5.3 - - - - - -
15 Gymnopetalum cochinchinensis
(Lour.) Kurz
Fruit 7.6 - - - - + -
16 Holarrhena antidysenterica
(L.) Wall. ex A. DC.
Bark 2.1 + + - - - +
17 Impatiens balsamina L. Stem 5.2 - + - - + -
18 Manilkara achras (Mill.) Fosb. Fruit 26.7 + - + - - +
19 Millingtonia hortensis L.f. Flower 25.4 + + + - - -
20 Mitragyna speciosa Korth. Leaf 5.9 + + - - + -
21 Momordica charantia L. Vine 3.0 + - - - + -
22 Morinda citrifolia L. Fruit 7.3 + - + - + -
23 Murdannia loriformis (Hassk.)
R. Rao & Kammathy
Whole plant 7.6 + - - - + -
24 Oroxylum indicum (L.) Vent. Leaf 3.7 + + - - + -
25 Peltophorum pterocarpum
(DC.) Backer ex K. Heyne
Flower 7.1 + - - - - -
Bark 7.1 + + - - - +
26 Piper betle L. Leaf 12.4 - + - - + -
27 Piper nigrum L. Fruit 4.2 + - - - + -
Seed 4.2 + - - - + -
28 Piper retrofractum Vahl Fruit 7.0 - - - - + -
29 Piper sarmentosum Roxb Leaf 1.7 + - - - + -
30 Pluchea indica (L.) Less. Leaf 17.8 + + - - + -
31 Psidium guajava L. Leaf 8.0 + + - - + -
32 Punica granatum L. Pericarp 13.0 + + + - - +
33 Quercus infectoria G.Olivier Gall 37.8 + - - + - -
34 Quisqualis indica L. Flower 11.0 + - + + + -
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Table 2 Extraction yields and phytochemical constituents of tested medicinal plant extracts (Continued)
35 Rhizophora mucronata Lam. Fruit 10.7 + + - - - +
Bark 11.6 - + - - - +
36 Rhodomyrtus tomentosa
(Aiton) Hassk.
Stem 7.1 + + - - - +
37 Sandoricum indicum Cav. Root 4.0 + - - - + -
38 Tamarindus indica L. Leaf 4.8 + + + - + -
39 Terminalia bellirica
(Gaertn.) Roxb.
Fruit 14.8 + - - - + -
40 Terminalia chebula
(Gaertn.) Retz.
Fruit 5.9 + + - - - +
41 Terminalia sp. Fruit 23.9 + - - + - -
42 Theobroma cacao L. Pericarp 3.6 + + - - + -
Seed 5.9 - + + - - +
43 Vitex trifolia L. Leaf NDc + + - - + -
44 Xylocarpus granatum
J. Koenig.
Pericarp 2.6 + + - - + -
Seed 6.7 + + + - - +
aPercentage extract yields of medicinal plants were weight of crude extract per 100 g of dried plant materials.
bPhytochemincal constituents: 1, alkaloids; 2, condensed tannins; 3, flavonoids; 4, hydrolysable tannins; 5, steroids and 6, triterpenoids; ‘-’ indicates absence of
phytoconstituents ‘+’ indicates presence of phytoconstituents.
cND Not determined.
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significantly higher than the intrinsic antibacterial activ-
ity of the extracts (Table 1).
To explore the potential of developing a more powerful
combination therapy of these medicinal plants with novo-
biocin, we determined the resistant modifying ability of
varying concentrations of the extracts from 7.8 to
250 μg/ml by growth inhibition assay as illustrated in
Figure 1. Holarrhena antidysenterica extract which concen-
trations ranging from 7.8 to 62.5 μg/ml possessed no intrin-
sic anti-acinetobacter activity (Figure 1A) was demonstrated
to be a powerful RMA in combination with novobiocin
against this pathogen.
Our preliminary phytochemical test revealed that alka-
loids were common principles among the effective extracts.
In addition to alkaloids, other compounds including con-
densed tannins, triterpenoids, flavonoids, hydrolysable tan-
nins, and steroids were detected (Table 2). Although the
antibiotic resistant modifying ability of active principles of
the effective medicinal plants has never been investigated,
plant-derived alkaloids have been well-clarified as efflux
pump inhibitors (EPIs) for Gram positive bacteria [15,16].
Recent evaluation of 13 phyto-alkaloids for their EPI poten-
tial against staphylococcal isolates revealed that 60% and
30% of the tested compounds exhibited the activity against
methicillin resistant Staphylococcus aureus (MRSA) and
methicillin susceptible S. aureus (MSSA), respectively [16].
Four plant-derived alkaloids consisting of reserpine, quin-
ine, harmaline, and piperine possessed notable potential EPIactivities on both MRSA and MSSA [16]. More import-
antly, their mechanisms of actions as a RMA have been
proposed. Piperine was recorded as an inhibitor of MdeA
[17] and NorA [18] efflux pumps of S. aureus and Rv1258c
efflux pump of Mycobacterium tuberculosis [19]. Reserpine
was found as an inhibitor of Bmr efflux pump in Bacillus
subtilis, Tet(K) and NorA efflux pumps of S. aureus [20]. In
addition to phyto-alkaloids, several plant-derived polyphe-
nols such as epigallocatechin gallate of Camellia sinesis,
tellimagrandin I and rugosin B isolated from Rosa canina
have been established as useful RMAs with different
mechanisms of actions including inhibitions of adapted
drug target sites or enzymatic degradation of drugs [4].
Intensive investigations on plant-derived compounds as
RMAs have been performed in Gram-positive, but relatively
very few studies have been carried out to evaluated RMA
activities of plant-derived compounds on Gram-negative
bacteria [21-23].
In the last decade multidrug resistance in A. baumannii
became a serious growing problem worldwide. Colistin, an
old antibiotic with risk toxicity, has recently been brought
back into use to treat MDR bacteria as a stopgap measure
until new antibiotics can be developed [24]. A number of
workers have proposed the synergistically action combin-
ation of conventional antibiotics with RMA act synergistic-
ally against MDR Gram-negative bacteria [4,25,26]. We
have demonstrated that certain plant ethanol extracts
significantly enhanced the activity of novobiocin against
A. baumannii. Holarrhena antidysenterica is of interest
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antibacterial activity, but in combination with sub-MIC of
novobiocin led to a marked decrease in the bacterial
growth. Alkaloids were proposed as active principles of the
plant that possessed antibacterial activity on S. aureus, S.
epidermidis, Streptococcus faecalis, B. subtilis, Escherichia
coli, and Pseudomonas aeruginosa [27-29]. Some of the
alkaloids such as pubadysone, pubescine, norholadiene,
pubescimine, puboestrene, pubamide, and naringenin was
isolated form bark, seeds, and leaves of this plant [30-32].
Our previous investigation demonstrated that ellagic acid
which acts as an efflux pump inhibitor exhibited a syner-
gistic effect with novobiocin and other aminocoumarins
against both A. baumannii ATCC 19606 and MDR A. bau-
mannii [9]. Ethylenediaminetetraacetic acid and polyethy-
leneimine that disturb outer membrane permeability have
been reported as RMA for novobiocin against P. aerugi-
nosa and Stenotrophomonas morelense [33,34]. Similarly,
berry-derived phenolic compounds that efficiently destabi-
lized outer membrane permeability resulted in increase in
novobiocin susceptibility of Salmonella enterica serotype
Typhimurium [35].
Since intrinsic novobiocin resistance in A. baumannii is
related to the synergistic interaction between limited outer
membrane permeability and energy-dependent multidrug
efflux pumps [36,37], the RMA for novobiocin possibly
acts as a permeabilizer and/or an efflux pump inhibitor.
Conclusion
The RMA activity of Thai medicinal plants in combination
with novobiocin against A. baumannii is reported for the
first time. These findings led us to the development of a
new generation of phytopharmaceuticals that using plant-
derived compounds in combination with existing antibio-
tics to treat MDR A. baumannii that currently are almost
untreatable. Its mechanism of action as well as the active
constituents of a promising plant, Holarrhena antidysen-
terica should be further investigated.
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